Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 300 500 KRW 1.18%
Market Cap: 16T KRW
Have any thoughts about
Alteogen Inc?
Write Note

Alteogen Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alteogen Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Alteogen Inc
KOSDAQ:196170
Operating Income
-â‚©5.7B
CAGR 3-Years
39%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Operating Income
â‚©369.6B
CAGR 3-Years
-22%
CAGR 5-Years
6%
CAGR 10-Years
9%
SK Bioscience Co Ltd
KRX:302440
Operating Income
-â‚©12B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Operating Income
â‚©33.8B
CAGR 3-Years
-20%
CAGR 5-Years
-9%
CAGR 10-Years
-9%
H
Hugel Inc
KOSDAQ:145020
Operating Income
â‚©156.5B
CAGR 3-Years
14%
CAGR 5-Years
19%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Operating Income
â‚©102.2B
CAGR 3-Years
31%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

Alteogen Inc
Glance View

Market Cap
16T KRW
Industry
Biotechnology

Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.

Intrinsic Value
33 513.79 KRW
Overvaluation 89%
Intrinsic Value
Price

See Also

What is Alteogen Inc's Operating Income?
Operating Income
-5.7B KRW

Based on the financial report for Sep 30, 2024, Alteogen Inc's Operating Income amounts to -5.7B KRW.

What is Alteogen Inc's Operating Income growth rate?
Operating Income CAGR 5Y
11%

Over the last year, the Operating Income growth was -29%. The average annual Operating Income growth rates for Alteogen Inc have been 39% over the past three years , 11% over the past five years .

Back to Top